Successful Milestone in Lead Discovery Collaboration with Nerviano Medical Sciences
ChemDiv, Inc. announced that it has earned the successful milestone in its lead discovery collaboration with Nerviano Medical Sciences (NMS). In October 2007, ChemDiv and NMS expanded their partnership to discover and develop potential anticancer agents. Under the terms of the collaboration, ChemDiv will receive a milestone payment for successful delivery of a lead molecule to NMS, in addition to research fees earned for discovery services.
Nikolay Savchuk, President and CEO of ChemDiv, Inc. commented: “We are very pleased to be able to deliver high value to Nerviano's oncology program applying our Discovery outSource SM platforms. ChemDiv's rational approach to small molecule discovery and strengths in medicinal chemistry and pre-clinical biology will help to secure further success in this collaboration. Once again, ChemDiv’s leadership in discovery and development services has been validated through our work with Nerviano, one of Europe’s largest oncology-focused developers.”
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.